Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK.
Eckhardt SG, et al. Among authors: kuhn jg.
J Clin Oncol. 2000 Dec 15;18(24):4086-97. doi: 10.1200/JCO.2000.18.24.4086.
J Clin Oncol. 2000.
PMID: 11118470